Journal of Experimental Medicine Submission Guide: What to Prepare Before You Submit
Journal of Experimental Medicine's submission process, first-decision timing, and the editorial checks that matter before peer review begins.
Readiness scan
Before you submit to Journal of Experimental Medicine, pressure-test the manuscript.
Run the Free Readiness Scan to catch the issues most likely to stop the paper before peer review.
Key numbers before you submit to Journal of Experimental Medicine
Acceptance rate, editorial speed, and cost context — the metrics that shape whether and how you submit.
What acceptance rate actually means here
- Journal of Experimental Medicine accepts roughly ~15-25% of submissions — but desk rejection runs higher.
- Scope misfit and framing problems drive most early rejections, not weak methodology.
- Papers that reach peer review face a different bar: novelty, rigor, and fit with the journal's editorial identity.
What to check before you upload
- Scope fit — does your paper address the exact problem this journal publishes on?
- Desk decisions are fast; scope problems surface within days.
- Cover letter framing — editors use it to judge fit before reading the manuscript.
How to approach Journal of Experimental Medicine
Use the submission guide like a working checklist. The goal is to make fit, package completeness, and cover-letter framing obvious before you open the portal.
Stage | What to check |
|---|---|
1. Scope | Manuscript preparation |
2. Package | Submission via Manuscript Central |
3. Cover letter | Editorial assessment |
4. Final check | Peer review |
Quick answer: This Journal of Experimental Medicine submission guide starts with the main editorial reality. JEM's public guidance is generous on formatting at first submission, but not generous on scientific posture. Rockefeller University Press explicitly allows format-neutral first submissions and welcomes presubmission inquiries, yet the journal's standards still center on a strong conceptual advance in experimental medicine. That means the hard part is not formatting the files. It is proving that the manuscript bridges mechanism and disease biology convincingly enough for a broad JEM readership.
Run a Journal Of Experimental Medicine pre-submission readiness check before clicking submit, or work through this guide manually.
From our manuscript review practice
The most common JEM mistake is assuming that strong immunology plus a disease model automatically equals experimental medicine. At this journal, the bridge between mechanism and disease has to carry real weight.
How this page was reviewed
This page was reviewed against the Rockefeller University Press JEM submission guidelines, JEM instructions for authors, JEM editorial policies, JEM reference guidelines, the JEM online submission system, recent JEM issue patterns, and Manusights internal analysis of experimental-medicine submissions.
Source limitations: JEM publishes unusually specific submission, cover-letter, presubmission-inquiry, Source Data, and SciScore workflow requirements. It does not publish manuscript-level desk-screen notes. Manusights observations are anonymized pre-submission review patterns and are included only as practical author guidance.
After the official guidance, the practical screen is the set of specific failure patterns we see when the title, abstract, summary, figures, Source Data files, methods, cover letter, and reviewer suggestions do not prove the mechanism-disease bridge.
For the underlying journal profile, see Journal of Experimental Medicine.
Journal of Experimental Medicine: Key submission facts
Requirement | Details |
|---|---|
2024 JIF | 10.6 |
Publisher | Rockefeller University Press |
First-submission format | Format-neutral |
Presubmission route | Welcome through the online system, with replies typically within about two days |
Core research formats | Articles and Brief Definitive Reports |
Operational detail | Title under 100 characters, abstract up to 160 words, short summary around 40 words |
How should JEM compare against neighboring journals?
Target | Best fit | Risk if chosen loosely | Package proof editors need |
|---|---|---|---|
Journal of Experimental Medicine | Mechanism tied to disease biology for a broad experimental-medicine readership | The paper reads as pure mechanism or pure disease phenotype | Abstract, figures, methods, Source Data, and cover letter all make the mechanism-disease bridge explicit |
Immunity | Immune mechanism with field-level immunology ownership | The disease model is present but not central to the immunology advance | Figures and methods prove immune-cell mechanism, not only disease association |
JCI | Translational or clinical-investigation story with patient-facing consequence | The mechanistic depth is stronger than the clinical consequence | Patient samples, clinical context, and cover letter support the translational claim |
Disease-specialty journal | Narrow disease audience, biomarker, therapeutic, or cohort-specific contribution | JEM would see the readership as too narrow | Abstract and references show why specialist readers are the natural primary audience |
What JEM is actually screening for
JEM is not just an immunology journal and not just a disease journal. Editors are usually asking:
- does the paper connect mechanism to disease biology in a way that matters to experimental medicine readers
- does the evidence move beyond phenotype description into a real causal or explanatory chain
- is the work broad enough for JEM rather than better owned by a narrower specialty title
- does the manuscript feel scientifically mature enough that a format-neutral first submission is still clearly review-ready
That is why strong manuscripts still fail here. The individual parts can be impressive and the bridge between them can still be too weak.
Before you submit
Pressure-test these questions before upload:
- the title and abstract make both the mechanistic gain and the disease consequence visible early
- the evidence goes beyond a striking phenotype into a stronger causal story
- the work would matter to experimental-medicine readers outside your exact specialty
- the manuscript is strong enough to survive JEM's first editorial read without needing a rescue explanation in the cover letter
- the cover letter can explain why JEM is the right owner instead of Immunity, JCI, or a more disease-specific journal
If those answers are weak, the paper is usually early for this target.
What the official JEM guidance makes explicit
Rockefeller University Press gives authors more detail than many journals do, and those details reveal the real editorial posture.
Official signal | Why it matters |
|---|---|
Presubmission inquiries are welcome and typically answered quickly | Use the route when the level or readership call is genuinely uncertain |
First submissions are format-neutral | JEM is testing scientific maturity, not template obedience, at first pass |
The title page must include full authors and affiliations, plus full title, abstract, and short running title | Basic package discipline still matters even in a format-neutral workflow |
The cover letter should describe conceptual advance, related or competing papers, conflicts, and reviewer requests or exclusions | Editorial context is part of readiness here |
JEM asks for a short summary and a tightly limited abstract | Broad readability and editorial clarity are expected early |
The practical implication is simple: JEM reduces formatting friction, not scientific friction.
The package that works best here
1. A manuscript whose conceptual advance appears on page one
Editors should not have to infer the mechanistic importance from deep in the Results section. The first page needs to show the disease question, the mechanism, and why experimental-medicine readers should care.
2. A mechanism that is stronger than the phenotype
This is where many manuscripts stall. JEM papers often begin with a striking phenotype, but they do not stop there. The paper usually needs a more complete causal chain than authors expect.
3. A disciplined title, summary, and abstract
The official JEM instructions are specific here because the journal cares about how quickly the claim becomes legible. If the short summary, title, and abstract cannot state the advance clearly, the manuscript often is not positioned well enough yet.
4. A cover letter that reads like an editorial memo
At this journal, the cover letter should explain conceptual advance, related work, reviewer fit, and any submission context the editors need to evaluate the paper cleanly. That is not busywork. It is part of the initial editorial screen.
Common mistakes at this journal
1. Disease phenotype without enough mechanism
This is one of the most common near-misses. The disease model can be compelling and the causal explanation can still feel one level too thin.
2. Mechanism without enough disease consequence
The opposite failure also happens. Strong immunology or cell biology papers can still feel better owned by another journal if the experimental-medicine consequence is not carrying enough weight.
3. A paper that is too narrow for JEM's readership
JEM wants broad experimental-medicine value. Narrow but rigorous papers often need a specialty venue instead.
Before upload, a JEM readiness check can tell you whether the weakness is journal fit, evidence maturity, or first-read framing.
What the cover letter should do
The official guidance already points you in the right direction. The cover letter should answer:
- what the conceptual advance is
- why the advance matters in disease or experimental-medicine terms
- what related or competing work is in play
- who should and should not review the paper
- whether the manuscript connects to a presubmission inquiry or transfer context
The strongest JEM cover letters sound precise rather than promotional. They tell the editor how to see the paper correctly.
Read the public instructions for mechanics, then pressure-test the package the way an editor will see it. The review tells you whether YOUR paper passes the Journal of Experimental Medicine fit screen before upload, especially around mechanism-disease bridge where one side is doing all the work, format-neutral first submission treated as a low-polish first submission, and neighboring-journal ownership hidden by a prestige-first target. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.
In our pre-submission review work with manuscripts targeting Journal of Experimental Medicine
In our pre-submission review work with manuscripts targeting Journal of Experimental Medicine, three patterns show up repeatedly before external review begins. They are visible in the title, abstract, short summary, figures, Source Data files, methods, cover letter, reviewer suggestions, and presubmission-inquiry history.
Mechanism-disease bridge where one side is doing all the work
In our pre-submission review work with immunology, infection, cancer, inflammation, vascular biology, neuroimmune, and disease-model manuscripts targeting JEM, the most common failure is an uneven bridge. Sometimes the disease phenotype is strong, but the mechanism is thin: the figures show disease rescue, pathology, or patient association without proving the causal pathway. Sometimes the mechanism is elegant, but the disease consequence is decorative: the manuscript reads like Immunity, Cell Reports, or Journal of Cell Biology with a disease model added late. JEM is strongest when both sides carry weight.
The manuscript components should make that bridge visible early. The title and abstract should name both the mechanistic insight and the disease-biology consequence. The short summary should not be a generic table-of-contents description. The figures should show that the mechanism explains a disease-relevant phenotype, not only that both are present. The methods should make model choice, controls, patient material, or animal work credible. The cover letter should tell the editor why this is experimental medicine rather than pure immunology, pure cell biology, or a disease-specialty paper.
If the manuscript is mainly immune mechanism, Immunity or Nature Immunology may be cleaner. If it is mainly clinical translation, JCI or Science Translational Medicine may own the audience. If it is host-pathogen specific, Cell Host & Microbe may be more natural. JEM fits when the paper's abstract, figures, methods, and cover letter all prove that mechanism and disease biology are inseparable.
Format-neutral first submission treated as a low-polish first submission
JEM's format-neutral first-submission policy is useful, but it creates a trap. We see authors submit a scientifically strong package with a loose title, underworked abstract, thin short summary, generic cover letter, incomplete Source Data plan, or vague reviewer logic because they assume formatting flexibility means editorial flexibility. It does not. The official guidance reduces cosmetic friction, but it does not reduce the need for a polished first-read argument.
The stronger JEM package uses the first submission to help the editor see the paper quickly. The title stays disciplined. The abstract names the conceptual advance and avoids burying the disease consequence. The short summary reads like a precise editorial note. The cover letter explains the conceptual advance, related or competing work, presubmission-inquiry context if relevant, conflicts, and reviewer logic. The figure package is organized so Source Data requirements for gels and Western blots are not an afterthought. The methods are complete enough to support SciScore-style rigor and reproducibility checks at revision.
This is why JEM misses are often positioning errors rather than failed science. A mechanism-plus-disease first-read check can identify whether the initial package is editorially ready before the formal upload.
Neighboring-journal ownership hidden by a prestige-first target
The third pattern is a paper that is strong but owned by another readership. We see manuscripts targeting JEM because it is prestigious, even though the real audience is Immunity, Journal of Clinical Investigation, Cell Host & Microbe, Science Translational Medicine, Blood, Cancer Cell, or a disease-specialty journal. This usually appears in the references and cover letter. The authors cite JEM, but the scientific conversation they are actually entering belongs elsewhere.
The stronger submission makes an honest ownership argument. If the paper is immunology-led, the cover letter should explain why the disease-biology bridge makes JEM better than Immunity or Nature Immunology. If the paper is translational medicine, it should explain why the mechanistic experimental component makes JEM better than JCI or Science Translational Medicine. If the paper is host-pathogen biology, it should explain why JEM's experimental-medicine readership is more appropriate than Cell Host & Microbe. The abstract, figures, methods, references, and reviewer suggestions should all point to the same answer.
This routing discipline matters because editors do not only ask whether the work is good. They ask whether JEM readers should own it. A manuscript that cannot answer that question may be better submitted elsewhere first, even when the science is strong.
JEM versus nearby alternatives
Journal | Best fit | Think twice if |
|---|---|---|
Journal of Experimental Medicine | Mechanistic disease biology and broad experimental medicine | The work is mainly pure immunology or narrow specialty disease biology |
Immunity | Elite mechanistic immunology | The disease-biology bridge is stronger than the immunology-alone story |
Journal of Clinical Investigation | Translational medicine with stronger clinical-facing emphasis | The manuscript is more mechanism-driven experimental medicine than clinical translation |
Cell Host & Microbe | Host-pathogen and infection work with clear infection ownership | The broader experimental-medicine frame is stronger than the infection-only frame |
The honest choice usually depends on which readership should remember the paper, not only on brand tier.
Submission portal
Journal of Experimental Medicine submissions go through Rockefeller University Press's online submission system, accessible from the journal's Instructions for Authors and Submission Guidelines. JEM uses format-neutral first submissions: manuscripts do not need to be formatted to journal specifications at first submission. Presubmission inquiries are welcome via the online submission system and typically receive responses within two days.
JEM accepts Articles and Brief Definitive Reports. Reviews and Perspectives require prior editorial contact via jem@rockefeller.edu (212-327-8575) before submission.
Submission checklist
JEM requires these at first submission (format-neutral; specific formatting follows at revision):
- main manuscript file with all authors and affiliations on the title page
- full title (no more than 100 characters), abstract, and short running title
- cover letter describing the conceptual advance, related or competing papers in press or under consideration elsewhere, conflicts of interest, and whether the submission is in response to a presubmission inquiry
- short summary for the table of contents
- comprehensive Materials and Methods section (JEM does NOT permit supplemental Materials and Methods, and Methods sections must NOT simply reference a previous publication; there is no length limit on Methods)
- Source Data files for every figure containing gels and Western blots (mandatory)
- 1 figure with gel or Western blot data is enough to require complete Source Data support
- ethics statements for animal protocols (IACUC), human-subjects work (IRB), and informed consent
- competing-interests declaration
- data and code availability statements with deposit accessions
- author contributions statement using CRediT roles
- ORCID iDs for all authors
- declaration of generative AI use
- suggested reviewers and excluded reviewers with rationale
- at revised submission, the Methods section is transmitted through the submission system interface to SciScore for a reproducibility score and rigor / key-resources report
- for revised submissions, point-by-point reviewer response and marked-up manuscript
In our pre-submission review work for JEM, the most common artifact-related issue is incomplete Source Data for gels and Western blots. JEM enforces this requirement consistently: the journal accepts incomplete formatting at first submission but does not accept missing Source Data on figures it cares about. Submissions that defer Source Data to revision face routine technical-screen returns rather than peer review.
Editorial triage timeline
In our pre-submission review work for JEM, manuscripts move through a four-stage editorial timeline shaped by the journal's professional in-house editorial team and explicit presubmission-inquiry channel.
Day 0 to 2: Online submission intake and presubmission-inquiry track
The Rockefeller submission system performs an automated technical check. Presubmission inquiries (separate from formal submissions) receive editorial responses typically within two days; the inquiry response shapes whether and how to submit.
Day 2 to 21: Editor desk-screen on the mechanism-disease bridge
A JEM editor reviews scope fit against the journal's experimental-medicine framing: does the paper bridge mechanism and disease biology with sufficient broad readership stakes? Pure phenotype, pure mechanism, and elegant-immunology-without-experimental-medicine submissions are routinely desk-rejected at this stage in favor of papers that carry the mechanism-disease bridge convincingly.
Week 3 to 8: External peer review
Manuscripts that pass desk-screen go to 2-3 reviewers selected for both the mechanism and the disease subfield. JEM editors actively shape reviewer selection to test the experimental-medicine claim.
Week 8 to 16: Decision, SciScore reproducibility report, and revision rounds
First decisions arrive at the 6-10 week median, typically as major or minor revision. Revised submissions are routed through SciScore for a reproducibility score and rigor report on the Methods. Revision cycles add 6-12 weeks each.
Readiness check
Run the scan while Journal of Experimental Medicine's requirements are in front of you.
See how this manuscript scores against Journal of Experimental Medicine's requirements before you submit.
Submit If
- the manuscript connects mechanism to disease biology in a way that matters broadly
- the paper is stronger than descriptive phenotype
- the title, summary, and abstract make the conceptual gain obvious early
- the cover letter can state the advance, context, and reviewer logic cleanly
- JEM is the most honest readership owner
Think Twice If
- the disease story is strong but the figures leave the causal chain incomplete
- the mechanism is elegant but the abstract and methods make the disease consequence mostly rhetorical
- the cover letter cannot explain why the real readership is not a tighter immunology, microbiology, or disease niche
- the manuscript would require major scientific rescue after submission to meet the claim level
Before upload, run a mechanism and disease readiness check to see whether the manuscript belongs here now or after another round of scientific tightening.
Frequently asked questions
JEM uses Rockefeller University Press's online submission system. The official submission guidelines say first submissions are format-neutral, presubmission inquiries are welcome, and the submission package should already include a disciplined title page, abstract, running title, and a cover letter that explains the conceptual advance.
JEM is strongest when a paper bridges mechanism and disease biology. In practice, editors are screening for experimental medicine rather than pure phenotype or pure mechanism alone.
The current official JEM guidance is unusually explicit about process details. Presubmission inquiries are welcome, first submissions are format-neutral, the title should stay under 100 characters, authors need a short summary for the table of contents, and the cover letter is expected to discuss conceptual advance, related work, conflicts, and reviewer requests or exclusions.
Common reasons include disease phenotype without enough mechanism, elegant immunology without enough experimental-medicine consequence, and manuscripts whose true audience is a narrower specialty journal rather than JEM's broader readership.
Sources
- JEM submission guidelines
- JEM instructions for authors
- JEM editorial policies
- JEM reference guidelines
- JEM about page
- JEM online submission system (jem.msubmit.net)
- Rockefeller University Press journals
- Clarivate Journal Citation Reports
- Recent JEM Article exemplars (illustrating the mechanism-disease bridge): DOI 10.1084/jem.20231300, DOI 10.1084/jem.20240127, DOI 10.1084/jem.20232225
Final step
Submitting to Journal of Experimental Medicine?
Run the Free Readiness Scan to see score, top issues, and journal-fit signals before you submit.
Target journal carried over: Journal of Experimental Medicine
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Same journal, next question
Supporting reads
Conversion step
Submitting to Journal of Experimental Medicine?
Anthropic Privacy Partner. Zero-retention manuscript processing.